glaxosmithkline plc firm taps zang to lead new drugs center glaxosmithkline plc said it appointed jingwu zang to head a major new research and development center in shanghai which will focus on neurodegenerative diseases the center aims to create drugs for disorders such as multiple sclerosis and parkinsons and alzheimers diseases it will eventually direct global discovery and development activities in its therapeutic area from drug target identification to late stage clinical studies dr zang the founding director and a professor at the institute of health sciences in shanghai will take up his position in june glaxos research head moncef slaoui said the move marked a significant expansion of the groups research effort 
